Literature DB >> 7506935

Hematopoietic receptors of class III receptor-type tyrosine kinases.

O Rosnet1, D Birnbaum.   

Abstract

Receptor-type tyrosine kinases (RTKs) constitute a family of proteins involved in growth and developmental processes. Class III RTKs are characterized by an extracellular region composed of five immunoglobulin-like domains and by a split tyrosine kinase domain. Some of the class III RTKs perform major functions in hematopoiesis and are the focus of this review. They are the colony-stimulating factor-1 (CSF1) and Steel factor (SLF) receptors, encoded by the FMS and KIT protooncogenes, respectively, and the product of the FLT3/FLK2 gene. The structural, biochemical, functional, and pathological features of these three receptors and genes are reviewed.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7506935

Source DB:  PubMed          Journal:  Crit Rev Oncog        ISSN: 0893-9675


  26 in total

1.  Roles of tyrosine 589 and 591 in STAT5 activation and transformation mediated by FLT3-ITD.

Authors:  Jennifer L Rocnik; Rachel Okabe; Jin-Chen Yu; Benjamin H Lee; Neill Giese; David P Schenkein; D Gary Gilliland
Journal:  Blood       Date:  2006-04-20       Impact factor: 22.113

Review 2.  Tales from the crypts: regulatory peptides and cytokines in gastrointestinal homeostasis and disease.

Authors:  Juanita L Merchant
Journal:  J Clin Invest       Date:  2007-01       Impact factor: 14.808

3.  Sequential activation of phoshatidylinositol 3-kinase and phospholipase C-gamma2 by the M-CSF receptor is necessary for differentiation signaling.

Authors:  R P Bourette; G M Myles; J L Choi; L R Rohrschneider
Journal:  EMBO J       Date:  1997-10-01       Impact factor: 11.598

4.  High-throughput proteomic profiling reveals mechanisms of action of AMG925, a dual FLT3-CDK4/6 kinase inhibitor targeting AML and AML stem/progenitor cells.

Authors:  Zhihong Zeng; Charlie Ly; Naval Daver; Jorge Cortes; Hagop M Kantarjian; Michael Andreeff; Marina Konopleva
Journal:  Ann Hematol       Date:  2021-03-31       Impact factor: 3.673

5.  Tyrosine phosphorylation of proteins in primary human myeloid leukemic cells stimulated by macrophage colony-stimulating factor: analysis by disease type and comparison with normal human hematopoietic cells.

Authors:  S Hagiwara; M Yagisawa; K Saeki; S Iki; A Urabe; T Mimura; A Miwa; A Togawa; M Higashihara; F Takaku; A Yuo
Journal:  Int J Hematol       Date:  2001-01       Impact factor: 2.490

6.  Separation and characterization of the activated pool of colony-stimulating factor 1 receptor forming distinct multimeric complexes with signalling molecules in macrophages.

Authors:  V Kanagasundaram; A Jaworowski; R Byrne; J A Hamilton
Journal:  Mol Cell Biol       Date:  1999-06       Impact factor: 4.272

Review 7.  Emerging FMS-like tyrosine kinase 3 inhibitors for the treatment of acute myelogenous leukemia.

Authors:  Hillary Prescott; Hagop Kantarjian; Jorge Cortes; Farhad Ravandi
Journal:  Expert Opin Emerg Drugs       Date:  2011-03-22       Impact factor: 4.191

8.  In vivo evidence for an instructive role of fms-like tyrosine kinase-3 (FLT3) ligand in hematopoietic development.

Authors:  Panagiotis Tsapogas; Lee Kim Swee; Anja Nusser; Natko Nuber; Matthias Kreuzaler; Giuseppina Capoferri; Hannie Rolink; Rhodri Ceredig; Antonius Rolink
Journal:  Haematologica       Date:  2014-01-24       Impact factor: 9.941

9.  Antileukemic effects of the novel, mutant FLT3 inhibitor NVP-AST487: effects on PKC412-sensitive and -resistant FLT3-expressing cells.

Authors:  Ellen Weisberg; Johannes Roesel; Guido Bold; Pascal Furet; Jingrui Jiang; Jan Cools; Renee D Wright; Erik Nelson; Rosemary Barrett; Arghya Ray; Daisy Moreno; Elizabeth Hall-Meyers; Richard Stone; Ilene Galinsky; Edward Fox; Gary Gilliland; John F Daley; Suzan Lazo-Kallanian; Andrew L Kung; James D Griffin
Journal:  Blood       Date:  2008-09-26       Impact factor: 22.113

Review 10.  ABT-869, a promising multi-targeted tyrosine kinase inhibitor: from bench to bedside.

Authors:  Jianbiao Zhou; Boon-Cher Goh; Daniel H Albert; Chien-Shing Chen
Journal:  J Hematol Oncol       Date:  2009-07-30       Impact factor: 17.388

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.